The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...

A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

It is now apparent that nearly every Trump appointee is a diehard anti-China high priest or priestess. That’s not just Marco ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

$510,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Implementation of the Inflation ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

First introduced in January, the bipartisan BIOSECURE Act was voted through by the House Committee on Oversight and Accountability, a few weeks after the Senate Homeland Security and Governmental ...

1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number Issues related to the 340B program reforms Drug cost and pricing ...

The China-US trade war has spread to the biotech industry, as the US BIOSECURE Act looks to dampen Chinese influence on a range of services, including contract manufacturing. Ben Hargreaves ...